(adds details, quotes)
BRUSSELS, May 18 (Reuters) - The head of the European Union's medicines agency Guido Rasi said on Monday an initial authorisation for U.S. pharmaceutical company Gilead's remdesivir as a COVID-19 treatment could be granted in coming days.
The European Medicines Agency (EMA) has already recommended the compassionate use of remdesivir, which allows a drug to be administered to patients even before it has been fully authorised.
"It might be that a conditional market authorisation can be issued in the coming days," Rasi told a hearing in the EU Parliament in Brussels.
Apart from remdesivir, Rasi said other possible treatments against COVID-19 that may be available fast are those based on monoclonal antibodies, which can "neutralize" the new coronavirus (SARS-CoV-2) that causes the illness COVID-19.
(Reporting by Francesco Guarascio; Editing by Alex Richardson and Louise Heavens)
Our Standards: The Thomson Reuters Trust Principles.